NASDAQ:NVAX - Novavax Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.53 +0.01 (+1.91 %) (As of 03/26/2019 12:05 PM ET)Previous Close$0.5201Today's Range$0.5250 - $0.548052-Week Range$0.49 - $2.58Volume6.23 million shsAverage Volume31.92 million shsMarket Capitalization$235.10 millionP/E Ratio-1.07Dividend YieldN/ABeta2.08 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland. Receive NVAX News and Ratings via Email Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NVAX Previous Symbol CUSIP67000210 CIK1000694 Webwww.novavax.com Phone240-268-2000Debt Debt-to-Equity RatioN/A Current Ratio2.62 Quick Ratio2.62Price-To-Earnings Trailing P/E Ratio-1.07 Forward P/E Ratio-1.30 P/E GrowthN/A Sales & Book Value Annual Sales$34.29 million Price / Sales6.86 Cash FlowN/A Price / Cash FlowN/A Book Value($0.44) per share Price / Book-1.21Profitability EPS (Most Recent Fiscal Year)($0.50) Net Income$-184,750,000.00 Net Margins-538.81% Return on EquityN/A Return on Assets-72.43%Miscellaneous Employees362 Outstanding Shares441,340,000Market Cap$235.10 million Next Earnings Date5/8/2019 (Estimated) OptionableOptionable Novavax (NASDAQ:NVAX) Frequently Asked Questions What is Novavax's stock symbol? Novavax trades on the NASDAQ under the ticker symbol "NVAX." How were Novavax's earnings last quarter? Novavax, Inc. (NASDAQ:NVAX) issued its earnings results on Monday, March, 18th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The biopharmaceutical company earned $6.13 million during the quarter, compared to the consensus estimate of $7.87 million. During the same quarter last year, the company earned ($0.16) EPS. View Novavax's Earnings History. When is Novavax's next earnings date? Novavax is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Novavax. What price target have analysts set for NVAX? 9 analysts have issued 1-year price objectives for Novavax's stock. Their predictions range from $1.00 to $5.00. On average, they anticipate Novavax's share price to reach $3.1811 in the next year. This suggests a possible upside of 500.2% from the stock's current price. View Analyst Price Targets for Novavax. What is the consensus analysts' recommendation for Novavax? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 sell ratings, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novavax. What are Wall Street analysts saying about Novavax stock? Here are some recent quotes from research analysts about Novavax stock: 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (3/22/2019) 2. HC Wainwright analysts commented, "We have a Buy rating and 12-month price target of $6. We’ve used a discounted cash flow (DCF) methodology based on projected 2020-2030 revenues from sales of to arrive at our 12-month price target of $6 for NVAX shares (25% discount rate and 2% terminal growth rate)." (2/28/2019) 3. Cantor Fitzgerald analysts commented, ": We reaffirm our Neutral rating and $2 PT on NVAX. We believe the company’s portfolio of vaccine candidates has the potential to meaningfully improve the prevention of important infectious diseases. We think the forthcoming release of top-line data from the ResVax Phase 3 trial may be an important catalyst for the stock with the potential to de-risk the company’s most- advanced asset. In our view, understanding the need for and access to additional capital to develop pipeline assets while retaining their potential value is key to evaluating the fair value of the stock." (1/29/2019) Has Novavax been receiving favorable news coverage? News stories about NVAX stock have been trending somewhat negative recently, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novavax earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. Are investors shorting Novavax? Novavax saw a increase in short interest during the month of February. As of February 28th, there was short interest totalling 79,183,640 shares, an increase of 9.2% from the February 15th total of 72,525,583 shares. Based on an average daily trading volume, of 20,276,016 shares, the days-to-cover ratio is presently 3.9 days. Currently, 20.9% of the company's shares are short sold. View Novavax's Current Options Chain. Who are some of Novavax's key competitors? Some companies that are related to Novavax include Sangamo Therapeutics (SGMO), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), Cellectis (CLLS), NanoString Technologies (NSTG), Nightstar Therapeutics (NITE), BAVARIAN NORDIC/S (BVNRY), Osiris Therapeutics (OSIR), Heska (HSKA), Acorda Therapeutics (ACOR), Twist Bioscience (TWST), Voyager Therapeutics (VYGR), MeiraGTx (MGTX), Scholar Rock (SRRK) and Replimune Group (REPL). What other stocks do shareholders of Novavax own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Opko Health (OPK), Synergy Pharmaceuticals (SGYP), General Electric (GE), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), Twitter (TWTR), Geron (GERN) and Celgene (CELG). Who are Novavax's key executives? Novavax's management team includes the folowing people: Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)Dr. Gregory M. Glenn, Pres of R&D (Age 65)Mr. Sven Andréasson M.B.A., Sr. VP of Corp. Devel. (Age 67) Who are Novavax's major shareholders? Novavax's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Northern Trust Corp (1.19%), Two Sigma Investments LP (0.86%), Millennium Management LLC (0.77%), Two Sigma Advisers LP (0.44%), Caption Management LLC (0.15%) and Rhumbline Advisers (0.14%). Company insiders that own Novavax stock include Barclay A Phillips, Gregory M Glenn, James F Young, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax. Which major investors are selling Novavax stock? NVAX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Chicago Equity Partners LLC, Virtus ETF Advisers LLC, MetLife Investment Advisors LLC, Paloma Partners Management Co, Creative Planning, California Public Employees Retirement System and D.A. Davidson & CO.. View Insider Buying and Selling for Novavax. Which major investors are buying Novavax stock? NVAX stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Millennium Management LLC, Caption Management LLC, Two Sigma Advisers LP, Sargent Investment Group LLC, TD Asset Management Inc., Rhumbline Advisers and Jane Street Group LLC. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gregory M Glenn, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax. How do I buy shares of Novavax? Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Novavax's stock price today? One share of NVAX stock can currently be purchased for approximately $0.53. How big of a company is Novavax? Novavax has a market capitalization of $233.91 million and generates $34.29 million in revenue each year. The biopharmaceutical company earns $-184,750,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Novavax employs 362 workers across the globe. What is Novavax's official website? The official website for Novavax is http://www.novavax.com. How can I contact Novavax? Novavax's mailing address is 20 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected] MarketBeat Community Rating for Novavax (NASDAQ NVAX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 518 (Vote Outperform)Underperform Votes: 360 (Vote Underperform)Total Votes: 878MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: How is Preferred Stock Different from Common Stock?